实验室质量何去何从:过程指标、实验室管理、结局问题、风险评估与经济价值
该文综述临床实验室质量评估,指出结构、过程与结局指标间关联罕见,部分质量指标已显示过程改进,但经济价值证明困难。结论建议聚焦7-14个过程监测器,结合实验室管理与风险评估以提升价值。
要点
- 建议临床实验室采用7-14个过程监测器,覆盖检测全过程并包含高风险样本质量指标。
- 实验室管理结合教育干预与测试订单/报告格式修订可改善测试订购,但结果接收改进较难。
- 风险评估通过平衡缺陷频率、潜在危害权重和检测难度重新排序质量监测器重要性。
核心结论
- 临床实验室应汇聚于更少(7-14个)而非更多(21-35个)过程监测器,监测器应覆盖实验室控制的检测全过程并包含高风险样本质量指标。
- 实验室管理结合教育干预与测试订单格式及结果报告方案修订可改善测试订购,但改善结果接收更困难。
- 风险评估通过平衡缺陷频率、潜在危害权重和检测难度三个概率重新排序质量监测器的重要性。
- 聚焦的通用共识质量指标、更积极的实验室检测管理以及正式风险评估的整合三者相辅相成,而非与经济价值竞争,反而增强经济价值。
研究设计与样本
- 对全球临床实验室质量评估文献进行选择性但世界范围的综述。
主要发现
- 一些质量指标如七个通用CAP Q-Tracks监测器已显示显著过程改进,其他措施揭示了改善测试选择和结果管理的关键机会。
- 澳大利亚病理学家学院关键指标监测与管理系统已部署从故障模式影响分析引入的风险计算作为结局的替代措施。
- 展示临床实验室检测质量的经济价值是一个挑战。
关键数值与推荐
- 建议临床实验室采用7-14个过程监测器而非21-35个。
- 监测器应覆盖实验室控制的检测全过程并包含高风险样本质量指标。
临床怎么用
- 临床实验室应聚焦少数共识过程监测器,覆盖检测全过程并优先高风险样本质量指标。
- 实施实验室管理,结合教育干预与测试订单及报告格式修订,以改善测试订购。
- 整合正式风险评估以重新排序质量监测器重要性,并增强经济价值。
局限性
- 结构、过程实验室措施与患者结局之间的联系很少被证明。
- 改善结果接收比改善测试订购更困难。
- 展示临床实验室检测质量的经济价值是一个挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: For 50 years, structure, process, and outcomes measures have assessed health care quality. For clinical laboratories, structural quality has generally been assessed by inspection. For assessing process, quality indicators (QIs), statistical monitors of steps in the clinical laboratory total testing, have proliferated across the globe. Connections between structural and process laboratory measures and patient outcomes, however, have rarely been demonstrated. METHODS: To inform further development of clinical laboratory quality systems, we conducted a selective but worldwide review of publications on clinical laboratory quality assessment. RESULTS: Some QIs, like seven generic College of American Pathologists Q-Tracks monitors, have demonstrated significant process improvement; other measures have uncovered critical opportunities to improve test selection and result management. The College of Pathologists of Australasia Key Indicator Monitoring and Management System has deployed risk calculations, introduced from failure mode effects analysis, as surrogate measures for outcomes. Showing economic value from clinical laboratory testing quality is a challenge. CONCLUSIONS: Clinical laboratories should converge on fewer (7-14) rather than more (21-35) process monitors; monitors should cover all steps of the testing process under laboratory control and include especially high-risk specimen-quality QIs. Clinical laboratory stewardship, the combination of education interventions among clinician test orderers and report consumers with revision of test order formats and result reporting schemes, improves test ordering, but improving result reception is more difficult. Risk calculation reorders the importance of quality monitors by balancing three probabilities: defect frequency, weight of potential harm, and detection difficulty. The triple approach of (1) a more focused suite of generic consensus quality indicators, (2) more active clinical laboratory testing stewardship, and (3) integration of formal risk assessment, rather than competing with economic value, enhances it.
引用
- Meier FA, Badrick TC, Sikaris KA, et al. What's to Be Done About Laboratory Quality? Process Indicators, Laboratory Stewardship, the Outcomes Problem, Risk Assessment, and Economic Value: Responding to Contemporary Global Challenges. Am J Clin Pathol. 2018. PMID: 29471323. doi:10.1093/ajcp/aqx135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。